
The Emerging Role of Molecular Testing in an Era of Precision Medicine - Non–Small Cell Lung Cancer
An online panel discussion with leading experts knowledgeable about the importance of utilizing molecular testing in the diagnosis of cancer patients, including Issues and perspectives from various stakeholders on molecular testing and next-generation sequencing. The education will also include individual patient-focused cases, which will give clinicians in oncology an opportunity to put into practice what they have learned and to further enhance their subject matter understanding, as well as to allow them to interact directly with clinical content experts.
This activity is supported by an educational grant from AstraZeneca

Moderator
Patrick Kiel, PharmD
Indiana University, Indianapolis, IN

Faculty
Gregory Durm, MD
Indiana University, Indianapolis, IN

Faculty
Anna Livers-Ertel, ANP-BC, MSN, OCN
Franciscan Health, Indianapolis, IN

The Emerging Role of Molecular Testing in an Era of Precision Medicine - Non-Small Cell Lung Cancer
Patrick Kiel, PharmD
Indiana University, Indianapolis, IN
Posted: 10/18/2017
Expires: 10/18/2018
Credits/Contact Hours: 1.0
You can no longer earn CE credit for this program, however, please participate in the education here:
* This link will take you to the
Educational Measures website.
These CME/CE/CPE certified activities are jointly provided by
![]() |
![]() |
![]() |
![]() |